Takeda Pharmaceuticals U.S.A. Inc.
1 Takeda Pkwy
About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Please click here for Takeda job opportunities.
Tweets by Takeda
810 articles with Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has entered into a research, development and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd.
Takeda Announces Publication of Study Utilizing State-of-the-Art Modeling to Better Understand Optimal Treatment Positioning for Patients with Ulcerative Colitis
Takeda today announced the publication of a study utilizing a novel simulation model to predict treatment response in patients with moderately to severely active ulcerative colitis and help better understand optimal treatment positioning.
Underlying Revenue grew +6.7% year-to-date, with Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) posting strong underlying revenue growth of +14.5%..
Takeda Pharmaceutical today announced that the FDA has granted Fast Track designation to TAK-426, Takeda’s purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate.
Another experimental Alzheimer's disease treatment has failed in a late-stage study.
Takeda Utilizes Social Media Analysis and Survey in a Study to Better Understand Patient Preferences When Seeking Treatment for Inflammatory Bowel Disease
Takeda announced today that a special "Putting Patients First" January issue of The American Journal of Gastroenterology published its analysis of patients with IBD.
Takeda Release: European Commission Approves ADCETRIS (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients
Takeda Pharmaceutical (TSE: 4502) today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Seattle Genetics Announces ADCETRIS (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Seattle Genetics, Inc. reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization for ADCETRIS (brentuximab vedotin) to include the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Arcturus Therapeutics Announces Expansion of Collaboration With Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders
Under the deal, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal related disorders using Arcturus’s wholly-owned LUNAR lipid-mediated delivery systems .and UNA Oligomer chemistry.
Amgen's migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
Will this new buy be enough for Celgene investors?
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Takeda And Tigenix Announce That Cx601 (Darvadstrocel) Has Received a Positive CHMP Opinion to Treat Complex Perianal Fistulas in Crohn's Disease
This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe.
As part of the licence agreement, Takeda has taken a strategic equity stake in Izana.
Takeda and Seattle Genetics to Present Positive Data from Phase III ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017.
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation From U.S. FDA for Treatment of Dravet Syndrome
Takeda and Ovid formed a global collaboration to develop and commercialize TAK-935/OV935 for the treatment of developmental and epileptic encephalopathies in January 2017.
Takeda Appoints Toshio Fujimoto, MD, MBA, as General Manager of the Health Innovation Park in Shonan
The appointment is effective as of December 1, 2017.
The clinical trial (ZIK-101) will evaluate safety and immunogenicity of TAK-426 in 240 subjects between the ages of 18 and 49 across the continental U.S. and U.S. territories.
Takeda and Cognition Kit Present Results From Digital Wearable Technology Study in Patients With Major Depressive Disorder (MDD)
Takeda and Cognition Kit today announced that the companies will present results from MDD-5003.